Itolizumab targets the CD6-ALCAM axis to limit T-cell responses and brain barrier diapedesis in multiple sclerosis.

González-Muñoz C, Baeten P, Hermans D, Hoeks C, De Bondt M, Duran G, Van Wijmeersch B, Schroten H, Ishikawa H, Crombet-Ramos T, et al.